DESIGN AND DEVELOPMENT OF RILPIVIRINE NANOPARTICLE CONTAINING CHITOSAN USING IONIC GELATION METHOD FOR HIV INFECTIONS
Objective: The primary objective of the current research was to prepare rilpivirine loaded Nanoparticles containing Chitosan using the ionic gelation method for HIV infections.
Methods: The nanoparticles of rilpivirine were prepared using the ionic gelation technique. Further, nanoparticles were characterized by Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and in vitro drug release.
Results: The optimized nanoparticles were found with a particle size of 130.30±5.29 nm (mean±SD) and entrapment efficiency (% EE) of 77.10±0.50%. Scanning electron microscopy technique exposed spherical particles with uniform size. It was observed that the nanoparticles created showed the absence of the crystalline nature of the drug and its switch to the amorphous state. Results showed that more than 45% of the pure drug is released in 50 min and after 90 min almost about 95% of the drug is released.
Conclusion: The research study concluded that the in vitro release profile of nanoparticles was found to be sustained up to 24 hr. Sustained release of the rilpivirine could improve patient obedience to drug regimens, growing action effectiveness.
2. De Cock KM, Jaffe HW, Curran JW. The evolving epidemiology of HIV/AIDS. AIDS 2012;26:1205-13.
3. Connor RI, Paxton WA, Sheridan KE, Koup RA. Macrophages and CD4+T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1. J Virol 1996;70:8758-64.
4. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR. Homozygous defect in HIV 1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
5. Gupta RK, Van de Vijver DAMC, Manicklal S, Wainberg MA. Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. Retrovirology 2013;10:82-5.
6. Achhra AC, Boyd MA. Antiretroviral regimens sparing agents from the nucleoside (tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Res Ther 2013;10:33.
7. O’Brien WA. Resistance against reverse transcriptase inhibitors. Clin Infect Dis 2000;30:185-92.
8. Paraschiv S, Otelea D, Baicus C, Tinischi M, Costache M. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania. Int J Infect Dis 2009;13:81-9.
9. Wood E, Hogg RS, Lima VD, Kerr T, Yip B. Highly active antiretroviral therapy and survival in HIV infected injection drug users. JAMA 2008;300:550-4.
10. Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C. Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis 2010;51:947-56.
11. Sharma R, Jhorar R, Goyal K, Kumar R, Sharma AK. Nanotechnological interventions in HIV drug delivery and therapeutics. Biointerface Res Appl Chem 2014;4:820-31.
12. Vedha Hari BN, Devendharan K, Narayanan N. Approaches of novel drug delivery systems for Anti-HIV agents. Int J Drug Dev Res 2013;5:16-24.
13. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomed 2010;5:533-47.
14. Das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Delivery Rev 2010;62:458-77.
15. Mahajan SD, Aalinkeel R, Law WC, Reynolds JL, Nair BB, Sykes DE, et al. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int J Nanomed 2012;7:5301-14.
16. Ojewole E, Mackraj I, Naidoo P, Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm 2008;70:697-710.
17. Vyas TK, Shah L, Amiji MM. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Delivery 2006;3:613-28.
18. Shahiwala A, Amiji MM. Nanotechnology-based delivery systems in HIV/AIDS therapy. Future HIV Ther 2007;1:49-59.
19. Lanao JM, Briones E, Colino CI. Recent advances in delivery systems for anti-HIV1 therapy. J Drug Target 2007;15:21-36.
20. Govender T, Ojewole E, Naidoo P, Mackraj I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Delivery 2008;15:493-501.
21. Iannazzo D, Pistone A, Galvagno S, Ferro S, De Luca L. Synthesis and anti-HIV activity of carboxylated and drug-conjugated multi-walled carbon nanotubes. Carbon 2015;82:548-61.
22. Vyas TK, Shah L, Amiji MM. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Delivery 2006;3:613-28.
23. Kinch MS, Patridge E. An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs. Drug Discovery Today 2014;19:1510-3.
24. Sharma M, Walmsley SL. Antiretroviral therapy in HIV/AIDS. Expert Opin Pharmacother 2014;15:395-405.
25. Piperno A, Giofre SV, Iannazzo D, Romeo R, Romeo G. Synthesis of C 4‘Truncated phosphonated carbocyclic 2‘-Oxa-3‘-azanucleosides as antiviral agents. J Org Chem 2010; 75:2798-805.
26. Romeo R, Giofre SV, Macchi B, Balestrieri E, Mastino A. Truncated reverse isoxazolidinyl nucleosides: a new class of allosteric HIV-1 reverse transcriptase inhibitors. Chem Med Chem 2012;7:565-9.
27. Romeo R, Carnovale C, Giofre SV, Romeo G, Macchi B. Truncated phosphonated C-1’-branched N,O-nucleosides: a new class of antiviral agents. Bioorg Med Chem 2012;20:3652-7.
28. Romeo R, Carnovale C, Giofre SV, Monciino G, Chiacchio MA. Enantiomerically pure phosphonated carbocyclic 2’-oxa-3’-azanucleosides: synth and bio eva. Molecules 2014;19:14406-16.
29. Mehellou Y, de Clercq E. Twenty-six years of anti-hiv drug discovery: Where do we stand and where do we go? J Med Chem 2010;53:521-38.
30. Thomas l, Mathew S. Biosynthesis, characterization, and anti-inflammatory study of hemigraphis colorata loaded silver nanoparticles. Asian J Pharma Clin Res 2019;12:188-92.
31. Pavithra K, Bhagawati ST, Manjunath K. Development and evaluation of tizanidine hydrochloride loaded solid lipid nanoparticles. Asian J Pharma Clin Res 2019;12:152-8.
This work is licensed under a Creative Commons Attribution 4.0 International License.